---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075175"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:20:37.677594+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026

## Summary
- Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
- Reiterated FY2025 total product revenue guidance of $250M-$300M.
- Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.
- Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.
- Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states.

## SEC filing metadata
- accession: 0001104659-25-075175
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/0001104659-25-075175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075175
- JSON: https://secwatch.observer/filing/0001104659-25-075175.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.